Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy Share LOS ANGELES & BOSTON--(BUSINESS WIRE)--Vida Ventures ("Vida†), a next-generation life sciences venture firm, today announced its fourth major Vida portfolio acquisition of 2025, capping an unprecedented year of strategic exits and reinforcing the firm's disciplined, science-first approach to company building and investing. Earlier today, Halda Therapeutics ann ...

Core Insights - Johnson & Johnson (JNJ) reported better-than-expected third-quarter 2025 results, continuing its streak of earnings and sales beats, and raised its top-line guidance for the year [1][4][7] Financial Performance - JNJ's Q3 earnings per share (EPS) reached $2.80, exceeding the Zacks Consensus Estimate by 1.1% and improving 15.7% year-over-year [4] - Sales grew 6.8% year-over-year to $23.99 billion, also surpassing the Zacks Consensus Estimate by 1% [4] - Sales from Innovative Medicines and MedTech segments both increased by 6.8% year-over-year [4] Product Performance - Sales of the multiple myeloma drug Darzalex surged 21.7% year-over-year to $3.67 billion [5] - Other oncology drugs, Erleada, Carvykti, and Tecvayli, saw sales growth of 18.4%, 83.5%, and 31.3% respectively [5] - However, sales of Imbruvica and Zytiga declined by 7.8% and 25.1% respectively [5] - In the MedTech segment, growth was driven by electrophysiology products and the Cardiovascular business [6] 2025 Outlook - JNJ raised its sales expectation for 2025 from $93.2-$93.6 billion to $93.5-$93.9 billion, with adjusted operational sales growth expected to be in the range of 3.5-4.0% [7] - The company anticipates adjusted EPS to be in the range of $10.80-$10.90 [7] Strategic Moves - JNJ announced plans to separate its Orthopaedics franchise, DePuy Synthes, which has been underperforming [8] - Following the positive results, Raymond James raised its price target for JNJ from $174 to $209, citing a strong product pipeline for future growth [8] ETFs Exposure - JNJ is a significant component in various healthcare ETFs, including: - iShares U.S. Pharmaceuticals ETF (IHE) with a 23.47% share and an 8.6% year-to-date gain [9] - Health Care Select Sector SPDR Fund (XLV) with an 8.88% share and a 3.6% year-to-date gain [11] - iShares U.S. Healthcare ETF (IYH) with an 8.55% share and a 3.9% year-to-date gain [12] - First Trust Nasdaq Pharmaceuticals ETF (FTXH) with a 7.56% share and a 7.6% year-to-date gain [13] - Fidelity MSCI Health Care Index ETF (FHLC) with a 7.52% share and a 5% year-to-date gain [14]

Core Viewpoint - Johnson & Johnson (JNJ) is set to report its third-quarter 2025 results on October 14, with expectations for sales of $23.74 billion and earnings of $2.77 per share, indicating a stable outlook for the company in the drug and biotech sector [1] Earnings Estimates - The Zacks Consensus Estimate for JNJ's earnings has remained unchanged at $10.86 per share for 2025, while the estimate for 2026 has slightly increased from $11.36 to $11.38 per share over the past 60 days [1][2] - JNJ's earnings surprise history shows an average surprise of 5.73% over the last four quarters, with a recent surprise of 4.14% [2][3] Sales Performance - Sales growth is anticipated from key products such as Darzalex, Tremfya, and Erleada, along with new drugs like Carvykti and Tecvayli [5][6] - The Zacks Consensus Estimate for Darzalex sales is $3.63 billion, while Tremfya is estimated at $1.3 billion [6] - The Innovative Medicines segment is projected to face challenges due to biosimilar competition for Stelara, which is expected to decline significantly [8][9] MedTech Segment Insights - JNJ's MedTech business is expected to show improvement driven by newly acquired cardiovascular businesses and strong performance in Surgical Vision and wound closure [12][13] - However, the MedTech segment faces challenges in China due to the volume-based procurement (VBP) program, which is likely to continue impacting sales [13] Stock Performance and Valuation - JNJ's stock has outperformed the industry with a year-to-date increase of 32.2%, compared to a 7.8% increase in the industry [16] - The company's shares are currently trading at a forward price/earnings ratio of 16.97, which is higher than the industry average of 15.88 [19] Business Model and Growth Outlook - JNJ's diversified business model focuses on Pharmaceuticals and MedTech following the separation of its Consumer Health segment [23] - The Innovative Medicine unit has shown a growth trend, with a 2.4% increase in sales in the first half of 2025, despite challenges [24] - JNJ is advancing its pipeline and has made acquisitions to strengthen its position in the neurological and psychiatric drug market [26] Future Expectations - JNJ considers 2025 a "catalyst year," expecting operational sales growth to accelerate in the second half of the year, driven by newly launched products [29]

Core Insights - Johnson & Johnson (JNJ) is expected to report its third-quarter results on October 14, with a focus on the performance of its Innovative Medicine segment, which includes several blockbuster drugs across various therapeutic areas [1] Sales Performance - J&J anticipates operational sales growth in its Innovative Medicine segment to be stronger in the second half of the year compared to the first half, despite the loss of exclusivity for its product Stelara and the negative impact from the Part D redesign [2] - The segment's sales increased by 2.4% on an organic basis in the first half of 2025, with expectations for continued growth driven by key products like Darzalex, Tremfya, and Erleada, alongside contributions from new drugs such as Carvykti, Tecvayli, Talvey, Rybrevant, Lazcluze, and Spravato [3][4] Competitive Landscape - The launch of several biosimilar versions of Stelara in the U.S. in 2025 has negatively impacted the Innovative Medicines segment's growth by 1170 basis points, with expectations for a steeper decline in the third quarter due to increased biosimilar entrants [5] - Rising competition from new oral drugs is likely to have affected sales of Imbruvica, while the Medicare Part D redesign under the Inflation Reduction Act has particularly hurt sales of drugs like Stelara, Imbruvica, Tremfya, and Erleada [6] Future Projections - Estimates for the Innovative Medicines unit suggest a compound annual growth rate (CAGR) of around 5% over the next three years [7] Competitive Positioning - J&J's key areas of focus are immunology and oncology, with significant competition from other large drugmakers such as Novartis, AstraZeneca, AbbVie, Amgen, Merck, Bristol-Myers, Roche, and Pfizer [8] Stock Performance and Valuation - J&J's shares have outperformed the industry year-to-date, rising by 30.5% compared to an 8.6% increase in the industry [9] - The company's shares are currently trading at a price/earnings ratio of 16.77, which is higher than the industry average of 15.96 and above its five-year mean of 15.64 [11] Earnings Estimates - The Zacks Consensus Estimate for J&J's 2025 earnings remains unchanged at $10.86 per share, while the estimate for 2026 has slightly increased from $11.36 to $11.37 per share over the past 60 days [12]

Core Viewpoint - Johnson & Johnson (JNJ) is set to report its first-quarter 2025 results on April 15, with sales and earnings estimates at $21.66 billion and $2.57 per share respectively. The earnings estimates for 2025 and 2026 have seen slight declines over the past 60 days [1]. Group 1: Earnings Performance - JNJ has consistently exceeded earnings expectations in the last four quarters, with an average earnings surprise of 4.43%. The last reported quarter showed a 2.0% earnings surprise [5]. - The company currently has an Earnings ESP of -2.53% and a Zacks Rank of 3 (Hold), indicating a mixed outlook for the upcoming earnings report [6]. Group 2: Sales Estimates and Drivers - Sales in JNJ's Innovative Medicines segment are expected to be driven by strong performances from key products like Darzalex, Tremfya, and Erleada, with respective sales estimates of $3.13 billion, $939.0 million, and $817.0 million [7][8]. - The sales estimate for the Innovative Medicine unit is $13.46 billion, while the MedTech segment is estimated at $8.14 billion, reflecting challenges in year-over-year comparisons [12][14]. Group 3: Competitive Landscape - The launch of biosimilars for Stelara is anticipated to impact its sales significantly, with estimates for Stelara sales at $1.64 billion [9][10]. - The MedTech business is facing headwinds in the Asia Pacific region, particularly in China, due to government cost containment efforts and competitive pressures [13]. Group 4: Strategic Developments - JNJ's diversified business model has been strengthened by the recent acquisition of Intra-Cellular Therapies for approximately $14.6 billion, enhancing its presence in the neurological and psychiatric drug market [24]. - The company is making progress with its pipeline and has been active in mergers and acquisitions, which is expected to bolster growth in its Innovative Medicine segment [23]. Group 5: Legal and Market Sentiment - Ongoing legal battles related to talc lawsuits have created a bearish sentiment around JNJ's stock, with a recent bankruptcy court ruling rejecting its proposed settlement plan [26]. - Despite potential challenges, JNJ has shown steady revenue and EPS growth, suggesting a long-term positive outlook for investors [27].